Comparison of the efficacy of glimepiride, metformin, and rosiglitazone monotherapy in korean drug-naïve type 2 diabetic patients: the practical evidence of antidiabetic monotherapy study

Although many anti-diabetic drugs have been used to control hyperglycemia for decades, the efficacy of commonly-used oral glucose-lowering agents in Korean type 2 diabetic patients has yet to be clearly demonstrated. We evaluated the efficacy of glimepiride, metformin, and rosiglitazone as initial t...

Full description

Saved in:
Bibliographic Details
Published in:Diabetes & metabolism journal 2011, 35(1), 123, pp.26-33
Main Authors: Yoon, Kun Ho, Shin, Jeong Ah, Kwon, Hyuk Sang, Lee, Seung Hwan, Min, Kyung Wan, Ahn, Yu Bae, Yoo, Soon Jib, Ahn, Kyu Jeung, Park, Sung Woo, Lee, Kwan Woo, Sung, Yeon Ah, Park, Tae Sun, Kim, Min Seon, Kim, Yong Ki, Nam, Moon Suk, Kim, Hye Soon, Park, Ie Byung, Park, Jong Suk, Woo, Jeong Taek, Son, Ho Young
Format: Article
Language:English
Subjects:
Diabetes mellitus, type 2
Glimepiride
Metformin
Original
Rosiglitazone
내과학
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
cited_by cdi_FETCH-LOGICAL-c560t-a453e75546952c1b241190e9a87f91b3df2475d4bb1f29ef1e7320c3f4a90f433
cites cdi_FETCH-LOGICAL-c560t-a453e75546952c1b241190e9a87f91b3df2475d4bb1f29ef1e7320c3f4a90f433
container_end_page 33
container_issue 1
container_start_page 26
container_title Diabetes & metabolism journal
container_volume 35
creator Yoon, Kun Ho
Shin, Jeong Ah
Kwon, Hyuk Sang
Lee, Seung Hwan
Min, Kyung Wan
Ahn, Yu Bae
Yoo, Soon Jib
Ahn, Kyu Jeung
Park, Sung Woo
Lee, Kwan Woo
Sung, Yeon Ah
Park, Tae Sun
Kim, Min Seon
Kim, Yong Ki
Nam, Moon Suk
Kim, Hye Soon
Park, Ie Byung
Park, Jong Suk
Woo, Jeong Taek
Son, Ho Young
description Although many anti-diabetic drugs have been used to control hyperglycemia for decades, the efficacy of commonly-used oral glucose-lowering agents in Korean type 2 diabetic patients has yet to be clearly demonstrated. We evaluated the efficacy of glimepiride, metformin, and rosiglitazone as initial treatment for drug-naïve type 2 diabetes mellitus patients in a 48-week, double-blind, randomized controlled study that included 349 Korean patients. Our primary goal was to determine the change in HbA1c levels from baseline to end point. Our secondary goal was to evaluate changes in fasting plasma glucose (FPG) levels, body weight, frequency of adverse events, and the proportion of participants achieving target HbA1c levels. HbA1c levels decreased from 7.8% to 6.9% in the glimepiride group (P
doi_str_mv 10.4093/dmj.2011.35.1.26
format article
fullrecord <record><control><sourceid>proquest_nrf_k</sourceid><recordid>TN_cdi_nrf_kci_oai_kci_go_kr_ARTI_221057</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><doaj_id>oai_doaj_org_article_1a5ce222e9564376917ae1df8f5d44f0</doaj_id><sourcerecordid>864785678</sourcerecordid><originalsourceid>FETCH-LOGICAL-c560t-a453e75546952c1b241190e9a87f91b3df2475d4bb1f29ef1e7320c3f4a90f433</originalsourceid><addsrcrecordid>eNpVUktvEzEQXiEQrULvnJBvcGiCn-tdDkhVxCNSJSRUztbEO06d7NqLdxMp_Cn-ADf-GE5SotaXsWe-x9ieonjN6EzSWrxvuvWMU8ZmQs3YjJfPikvOhZiWtNLPz3tdXxRXw7CmecmKal2_LC44U0JLRi-LP_PY9ZD8EAOJjoz3SNA5b8HuD-dV6zvsffINXpMORxdT58M1gdCQFAef6yP8igFJF0PM7AT9nvhANjEhBNKk7Woa4O_vHZJx3yPhpPGwxNFb0sPoMYzDh6Nrn8DmLLQEd9ktWDz4Qxj9mfDYYhi3zf5V8cJBO-DVQ5wUPz5_upt_nd5--7KY39xOrSrpOAWpBGqlZFkrbtmSS8ZqijVU2tVsKRrHpVaNXC6Z4zU6hlpwaoWTUFMnhZgU7066ITmzsd5E8Me4imaTzM33u4XhnFGlM3RxgjYR1qZPvoO0P-KPiZhWBlK-TIuGgbLIOcdalVLosmYakDWucrkX6WjW-njS6rfLDhubHytB-0T0aSX4-9zSzgha0YPmpHj7IJDizy0Oo-n8YLFtIWDcDqYqpa5UqauMpCekzb86JHRnF0bNYdpMnjZzmDYjlGGGl5ny5nF3Z8L_2RL_AOnL1bg</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>864785678</pqid></control><display><type>article</type><title>Comparison of the efficacy of glimepiride, metformin, and rosiglitazone monotherapy in korean drug-naïve type 2 diabetic patients: the practical evidence of antidiabetic monotherapy study</title><source>PubMed Central</source><creator>Yoon, Kun Ho ; Shin, Jeong Ah ; Kwon, Hyuk Sang ; Lee, Seung Hwan ; Min, Kyung Wan ; Ahn, Yu Bae ; Yoo, Soon Jib ; Ahn, Kyu Jeung ; Park, Sung Woo ; Lee, Kwan Woo ; Sung, Yeon Ah ; Park, Tae Sun ; Kim, Min Seon ; Kim, Yong Ki ; Nam, Moon Suk ; Kim, Hye Soon ; Park, Ie Byung ; Park, Jong Suk ; Woo, Jeong Taek ; Son, Ho Young</creator><creatorcontrib>Yoon, Kun Ho ; Shin, Jeong Ah ; Kwon, Hyuk Sang ; Lee, Seung Hwan ; Min, Kyung Wan ; Ahn, Yu Bae ; Yoo, Soon Jib ; Ahn, Kyu Jeung ; Park, Sung Woo ; Lee, Kwan Woo ; Sung, Yeon Ah ; Park, Tae Sun ; Kim, Min Seon ; Kim, Yong Ki ; Nam, Moon Suk ; Kim, Hye Soon ; Park, Ie Byung ; Park, Jong Suk ; Woo, Jeong Taek ; Son, Ho Young</creatorcontrib><description>Although many anti-diabetic drugs have been used to control hyperglycemia for decades, the efficacy of commonly-used oral glucose-lowering agents in Korean type 2 diabetic patients has yet to be clearly demonstrated. We evaluated the efficacy of glimepiride, metformin, and rosiglitazone as initial treatment for drug-naïve type 2 diabetes mellitus patients in a 48-week, double-blind, randomized controlled study that included 349 Korean patients. Our primary goal was to determine the change in HbA1c levels from baseline to end point. Our secondary goal was to evaluate changes in fasting plasma glucose (FPG) levels, body weight, frequency of adverse events, and the proportion of participants achieving target HbA1c levels. HbA1c levels decreased from 7.8% to 6.9% in the glimepiride group (P&lt;0.001), from 7.9% to 7.0% in the metformin group (P&lt;0.001), and from 7.8% to 7.0% (P&lt;0.001) in the rosiglitazone group. Glimepiride and rosiglitazone significantly increased body weight and metformin reduced body weight during the study period. Symptomatic hypoglycemia was more frequent in the glimepiride group and diarrhea was more frequent in the metformin group. The efficacy of glimepiride, metformin, and rosiglitazone as antidiabetic monotherapies in drug-naïve Korean type 2 diabetic patients was similar in the three groups, with no statistical difference. This study is the first randomized controlled trial to evaluate the efficacy of commonly-used oral hypoglycemic agents in Korean type 2 diabetic patients. An additional subgroup analysis is recommended to obtain more detailed information.</description><identifier>ISSN: 2233-6079</identifier><identifier>EISSN: 2233-6087</identifier><identifier>DOI: 10.4093/dmj.2011.35.1.26</identifier><identifier>PMID: 21537410</identifier><language>eng</language><publisher>Korea (South): Korean Diabetes Association</publisher><subject>Diabetes mellitus, type 2 ; Glimepiride ; Metformin ; Original ; Rosiglitazone ; 내과학</subject><ispartof>Diabetes and Metabolism Journal, 2011, 35(1), 123, pp.26-33</ispartof><rights>Copyright © 2011 Korean Diabetes Association 2011</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c560t-a453e75546952c1b241190e9a87f91b3df2475d4bb1f29ef1e7320c3f4a90f433</citedby><cites>FETCH-LOGICAL-c560t-a453e75546952c1b241190e9a87f91b3df2475d4bb1f29ef1e7320c3f4a90f433</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3080564/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC3080564/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,727,780,784,885,27924,27925,53791,53793</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/21537410$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://www.kci.go.kr/kciportal/ci/sereArticleSearch/ciSereArtiView.kci?sereArticleSearchBean.artiId=ART001534509$$DAccess content in National Research Foundation of Korea (NRF)$$Hfree_for_read</backlink></links><search><creatorcontrib>Yoon, Kun Ho</creatorcontrib><creatorcontrib>Shin, Jeong Ah</creatorcontrib><creatorcontrib>Kwon, Hyuk Sang</creatorcontrib><creatorcontrib>Lee, Seung Hwan</creatorcontrib><creatorcontrib>Min, Kyung Wan</creatorcontrib><creatorcontrib>Ahn, Yu Bae</creatorcontrib><creatorcontrib>Yoo, Soon Jib</creatorcontrib><creatorcontrib>Ahn, Kyu Jeung</creatorcontrib><creatorcontrib>Park, Sung Woo</creatorcontrib><creatorcontrib>Lee, Kwan Woo</creatorcontrib><creatorcontrib>Sung, Yeon Ah</creatorcontrib><creatorcontrib>Park, Tae Sun</creatorcontrib><creatorcontrib>Kim, Min Seon</creatorcontrib><creatorcontrib>Kim, Yong Ki</creatorcontrib><creatorcontrib>Nam, Moon Suk</creatorcontrib><creatorcontrib>Kim, Hye Soon</creatorcontrib><creatorcontrib>Park, Ie Byung</creatorcontrib><creatorcontrib>Park, Jong Suk</creatorcontrib><creatorcontrib>Woo, Jeong Taek</creatorcontrib><creatorcontrib>Son, Ho Young</creatorcontrib><title>Comparison of the efficacy of glimepiride, metformin, and rosiglitazone monotherapy in korean drug-naïve type 2 diabetic patients: the practical evidence of antidiabetic monotherapy study</title><title>Diabetes &amp; metabolism journal</title><addtitle>Diabetes Metab J</addtitle><description>Although many anti-diabetic drugs have been used to control hyperglycemia for decades, the efficacy of commonly-used oral glucose-lowering agents in Korean type 2 diabetic patients has yet to be clearly demonstrated. We evaluated the efficacy of glimepiride, metformin, and rosiglitazone as initial treatment for drug-naïve type 2 diabetes mellitus patients in a 48-week, double-blind, randomized controlled study that included 349 Korean patients. Our primary goal was to determine the change in HbA1c levels from baseline to end point. Our secondary goal was to evaluate changes in fasting plasma glucose (FPG) levels, body weight, frequency of adverse events, and the proportion of participants achieving target HbA1c levels. HbA1c levels decreased from 7.8% to 6.9% in the glimepiride group (P&lt;0.001), from 7.9% to 7.0% in the metformin group (P&lt;0.001), and from 7.8% to 7.0% (P&lt;0.001) in the rosiglitazone group. Glimepiride and rosiglitazone significantly increased body weight and metformin reduced body weight during the study period. Symptomatic hypoglycemia was more frequent in the glimepiride group and diarrhea was more frequent in the metformin group. The efficacy of glimepiride, metformin, and rosiglitazone as antidiabetic monotherapies in drug-naïve Korean type 2 diabetic patients was similar in the three groups, with no statistical difference. This study is the first randomized controlled trial to evaluate the efficacy of commonly-used oral hypoglycemic agents in Korean type 2 diabetic patients. An additional subgroup analysis is recommended to obtain more detailed information.</description><subject>Diabetes mellitus, type 2</subject><subject>Glimepiride</subject><subject>Metformin</subject><subject>Original</subject><subject>Rosiglitazone</subject><subject>내과학</subject><issn>2233-6079</issn><issn>2233-6087</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2011</creationdate><recordtype>article</recordtype><sourceid>DOA</sourceid><recordid>eNpVUktvEzEQXiEQrULvnJBvcGiCn-tdDkhVxCNSJSRUztbEO06d7NqLdxMp_Cn-ADf-GE5SotaXsWe-x9ieonjN6EzSWrxvuvWMU8ZmQs3YjJfPikvOhZiWtNLPz3tdXxRXw7CmecmKal2_LC44U0JLRi-LP_PY9ZD8EAOJjoz3SNA5b8HuD-dV6zvsffINXpMORxdT58M1gdCQFAef6yP8igFJF0PM7AT9nvhANjEhBNKk7Woa4O_vHZJx3yPhpPGwxNFb0sPoMYzDh6Nrn8DmLLQEd9ktWDz4Qxj9mfDYYhi3zf5V8cJBO-DVQ5wUPz5_upt_nd5--7KY39xOrSrpOAWpBGqlZFkrbtmSS8ZqijVU2tVsKRrHpVaNXC6Z4zU6hlpwaoWTUFMnhZgU7066ITmzsd5E8Me4imaTzM33u4XhnFGlM3RxgjYR1qZPvoO0P-KPiZhWBlK-TIuGgbLIOcdalVLosmYakDWucrkX6WjW-njS6rfLDhubHytB-0T0aSX4-9zSzgha0YPmpHj7IJDizy0Oo-n8YLFtIWDcDqYqpa5UqauMpCekzb86JHRnF0bNYdpMnjZzmDYjlGGGl5ny5nF3Z8L_2RL_AOnL1bg</recordid><startdate>20110201</startdate><enddate>20110201</enddate><creator>Yoon, Kun Ho</creator><creator>Shin, Jeong Ah</creator><creator>Kwon, Hyuk Sang</creator><creator>Lee, Seung Hwan</creator><creator>Min, Kyung Wan</creator><creator>Ahn, Yu Bae</creator><creator>Yoo, Soon Jib</creator><creator>Ahn, Kyu Jeung</creator><creator>Park, Sung Woo</creator><creator>Lee, Kwan Woo</creator><creator>Sung, Yeon Ah</creator><creator>Park, Tae Sun</creator><creator>Kim, Min Seon</creator><creator>Kim, Yong Ki</creator><creator>Nam, Moon Suk</creator><creator>Kim, Hye Soon</creator><creator>Park, Ie Byung</creator><creator>Park, Jong Suk</creator><creator>Woo, Jeong Taek</creator><creator>Son, Ho Young</creator><general>Korean Diabetes Association</general><general>대한당뇨병학회</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><scope>ACYCR</scope></search><sort><creationdate>20110201</creationdate><title>Comparison of the efficacy of glimepiride, metformin, and rosiglitazone monotherapy in korean drug-naïve type 2 diabetic patients: the practical evidence of antidiabetic monotherapy study</title><author>Yoon, Kun Ho ; Shin, Jeong Ah ; Kwon, Hyuk Sang ; Lee, Seung Hwan ; Min, Kyung Wan ; Ahn, Yu Bae ; Yoo, Soon Jib ; Ahn, Kyu Jeung ; Park, Sung Woo ; Lee, Kwan Woo ; Sung, Yeon Ah ; Park, Tae Sun ; Kim, Min Seon ; Kim, Yong Ki ; Nam, Moon Suk ; Kim, Hye Soon ; Park, Ie Byung ; Park, Jong Suk ; Woo, Jeong Taek ; Son, Ho Young</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c560t-a453e75546952c1b241190e9a87f91b3df2475d4bb1f29ef1e7320c3f4a90f433</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2011</creationdate><topic>Diabetes mellitus, type 2</topic><topic>Glimepiride</topic><topic>Metformin</topic><topic>Original</topic><topic>Rosiglitazone</topic><topic>내과학</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yoon, Kun Ho</creatorcontrib><creatorcontrib>Shin, Jeong Ah</creatorcontrib><creatorcontrib>Kwon, Hyuk Sang</creatorcontrib><creatorcontrib>Lee, Seung Hwan</creatorcontrib><creatorcontrib>Min, Kyung Wan</creatorcontrib><creatorcontrib>Ahn, Yu Bae</creatorcontrib><creatorcontrib>Yoo, Soon Jib</creatorcontrib><creatorcontrib>Ahn, Kyu Jeung</creatorcontrib><creatorcontrib>Park, Sung Woo</creatorcontrib><creatorcontrib>Lee, Kwan Woo</creatorcontrib><creatorcontrib>Sung, Yeon Ah</creatorcontrib><creatorcontrib>Park, Tae Sun</creatorcontrib><creatorcontrib>Kim, Min Seon</creatorcontrib><creatorcontrib>Kim, Yong Ki</creatorcontrib><creatorcontrib>Nam, Moon Suk</creatorcontrib><creatorcontrib>Kim, Hye Soon</creatorcontrib><creatorcontrib>Park, Ie Byung</creatorcontrib><creatorcontrib>Park, Jong Suk</creatorcontrib><creatorcontrib>Woo, Jeong Taek</creatorcontrib><creatorcontrib>Son, Ho Young</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>Directory of Open Access Journals</collection><collection>Korean Citation Index</collection><jtitle>Diabetes &amp; metabolism journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yoon, Kun Ho</au><au>Shin, Jeong Ah</au><au>Kwon, Hyuk Sang</au><au>Lee, Seung Hwan</au><au>Min, Kyung Wan</au><au>Ahn, Yu Bae</au><au>Yoo, Soon Jib</au><au>Ahn, Kyu Jeung</au><au>Park, Sung Woo</au><au>Lee, Kwan Woo</au><au>Sung, Yeon Ah</au><au>Park, Tae Sun</au><au>Kim, Min Seon</au><au>Kim, Yong Ki</au><au>Nam, Moon Suk</au><au>Kim, Hye Soon</au><au>Park, Ie Byung</au><au>Park, Jong Suk</au><au>Woo, Jeong Taek</au><au>Son, Ho Young</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Comparison of the efficacy of glimepiride, metformin, and rosiglitazone monotherapy in korean drug-naïve type 2 diabetic patients: the practical evidence of antidiabetic monotherapy study</atitle><jtitle>Diabetes &amp; metabolism journal</jtitle><addtitle>Diabetes Metab J</addtitle><date>2011-02-01</date><risdate>2011</risdate><volume>35</volume><issue>1</issue><spage>26</spage><epage>33</epage><pages>26-33</pages><issn>2233-6079</issn><eissn>2233-6087</eissn><abstract>Although many anti-diabetic drugs have been used to control hyperglycemia for decades, the efficacy of commonly-used oral glucose-lowering agents in Korean type 2 diabetic patients has yet to be clearly demonstrated. We evaluated the efficacy of glimepiride, metformin, and rosiglitazone as initial treatment for drug-naïve type 2 diabetes mellitus patients in a 48-week, double-blind, randomized controlled study that included 349 Korean patients. Our primary goal was to determine the change in HbA1c levels from baseline to end point. Our secondary goal was to evaluate changes in fasting plasma glucose (FPG) levels, body weight, frequency of adverse events, and the proportion of participants achieving target HbA1c levels. HbA1c levels decreased from 7.8% to 6.9% in the glimepiride group (P&lt;0.001), from 7.9% to 7.0% in the metformin group (P&lt;0.001), and from 7.8% to 7.0% (P&lt;0.001) in the rosiglitazone group. Glimepiride and rosiglitazone significantly increased body weight and metformin reduced body weight during the study period. Symptomatic hypoglycemia was more frequent in the glimepiride group and diarrhea was more frequent in the metformin group. The efficacy of glimepiride, metformin, and rosiglitazone as antidiabetic monotherapies in drug-naïve Korean type 2 diabetic patients was similar in the three groups, with no statistical difference. This study is the first randomized controlled trial to evaluate the efficacy of commonly-used oral hypoglycemic agents in Korean type 2 diabetic patients. An additional subgroup analysis is recommended to obtain more detailed information.</abstract><cop>Korea (South)</cop><pub>Korean Diabetes Association</pub><pmid>21537410</pmid><doi>10.4093/dmj.2011.35.1.26</doi><tpages>8</tpages><oa>free_for_read</oa></addata></record>
fulltext fulltext
identifier ISSN: 2233-6079
ispartof Diabetes and Metabolism Journal, 2011, 35(1), 123, pp.26-33
issn 2233-6079
2233-6087
language eng
recordid cdi_nrf_kci_oai_kci_go_kr_ARTI_221057
source PubMed Central
subjects Diabetes mellitus, type 2
Glimepiride
Metformin
Original
Rosiglitazone
내과학
title Comparison of the efficacy of glimepiride, metformin, and rosiglitazone monotherapy in korean drug-naïve type 2 diabetic patients: the practical evidence of antidiabetic monotherapy study
url http://sfxeu10.hosted.exlibrisgroup.com/loughborough?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T02%3A01%3A55IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_nrf_k&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Comparison%20of%20the%20efficacy%20of%20glimepiride,%20metformin,%20and%20rosiglitazone%20monotherapy%20in%20korean%20drug-na%C3%AFve%20type%202%20diabetic%20patients:%20the%20practical%20evidence%20of%20antidiabetic%20monotherapy%20study&rft.jtitle=Diabetes%20&%20metabolism%20journal&rft.au=Yoon,%20Kun%20Ho&rft.date=2011-02-01&rft.volume=35&rft.issue=1&rft.spage=26&rft.epage=33&rft.pages=26-33&rft.issn=2233-6079&rft.eissn=2233-6087&rft_id=info:doi/10.4093/dmj.2011.35.1.26&rft_dat=%3Cproquest_nrf_k%3E864785678%3C/proquest_nrf_k%3E%3Cgrp_id%3Ecdi_FETCH-LOGICAL-c560t-a453e75546952c1b241190e9a87f91b3df2475d4bb1f29ef1e7320c3f4a90f433%3C/grp_id%3E%3Coa%3E%3C/oa%3E%3Curl%3E%3C/url%3E&rft_id=info:oai/&rft_pqid=864785678&rft_id=info:pmid/21537410&rfr_iscdi=true